CAL-130 Racemate is the racemate of CAL-130. CAL-130 Racemate is a PI3Kδ inhibitor.

AGPS-IN-2i is a novel inhibitor of alkylglyceronephosphate synthase (agps), specifically impairing epithelial to mesenchymal transition (emt) by modulating e-cadherin, snail and mmp2 expression levels.

m-PEG10-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

m-PEG8-CH2COOH is a PEG--based PROTAC linker can be used in the synthesis of PROTACs.

m-PEG6-O-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

m-PEG4-CH2COOH is a PEG-based based PROTAC linker can be used in the synthesis of PROTACs.

m-PEG3-CH2COOH is a PEG-based based PROTAC linker can be used in the synthesis of PROTACs.

m-PEG11-alcohol is a PEG derivative containing a hydroxyl group. The hydroxyl group enables further derivatization or replacement with other reactive functional groups. The hydrophilic PEG spacer increases solubility in aqueous media.

Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a small-molecule ATP-competitive inhibitor of TGFβRI (ALK5) with an IC50 of 12.9 nM.

UHRF1 PHD inhibitor MLD4 is a specific compound that selectively inhibits the UHRF1-histone interaction (IC50=12.4 uM), targets the PHD finger of UHRF1, specifically disrupting histone H3 arginine 2 interactions with the PHD finger.UHRF1 PHD inhibitor MLD4 inhibited binding between H3K9me3(FAM) and UHRF1 with IC50 of 24-26 uM, displace UHRF1-histone H3 binding in cells.

NJH-2-075 is an alkyne-functionalized probe of EN523, retains binding to OTUB1 in vitro.

IMTPPE (SID3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells.

m-PEG5-CH2COOH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Diuron is a phenylurea herbicide that inhibits photosynthesis by preventing the formation of ATP and NADH. Diuron (2,500 ppm, dietary) increases the incidence of urinary bladder urothelial carcinomas in male and female mice by 73 and 27%, respectively.

Cipepofol (HSK3486), a sedative-hypnotic agent, is a gamma-aminobutyric acid (GABA) receptor potentiator.

RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.

CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist.

L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM, which is > 280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice.

Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor extracted from patent WO2014089048A1, compound 657, has an IC50 of 0.24 μM for Glutaminase 1 (GLS1).

Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.